Antibody-Drug Conjugates ADC Payload, Linker Toxicity & Patents

Antibody-Drug Conjugates (ADCs) have emerged as the fastest-growing modality in targeted oncology, combining the antigen selectivity of monoclonal antibodies with the cell-killing power of chemotherapeutic payloads. Molecular pharmacology research in the FDA oncology accelerated approval PFE MRK playbook investigates the engineering triad of antibody, linker, and payload.

The therapeutic index of an ADC hinges on linker chemistry. Stable cleavable linkers must withstand circulation in the bloodstream without prematurely releasing lethal payloads (such as topoisomerase I inhibitors or auristatins), releasing cytotoxic warheads only upon receptor-mediated internalization inside cancer cells.

Uncontrolled payload shedding in off-target tissues triggers dose-limiting systemic toxicities, including interstitial lung disease and severe neutropenia. Consequently, proprietary linkers and site-specific conjugation patents form the core intellectual property moats dictating multi-billion-dollar biopharma licensing transactions.